JNJ•benzinga•
Johnson & Johnson Announces TREMFYA Is The First And Only IL-23 Inhibitor To Reduce Both The Signs And Symptoms And The Progression Of Structural Damage In Adults Living With Active Psoriatic Arthritis
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 4, 2025 by benzinga